Supreme Court Orders Panel
To regulate pharma marketing practices, curb unethical freebies to doctors. The court directed the Union government to form a committee to examine the issue and recommend statutory regulations.
The Supreme Court directed the Union government to constitute an expert committee to examine whether pharmaceutical companies should be brought under a legally enforceable framework to curb unethical marketing practices.
A Bench of Justices Vikram Nath and Sandeep Mehta issued the directions while hearing a petition filed by the Federation of Medical and Sales Representatives’ Associations of India (FMRAI).
The petition raised concerns over pharmaceutical companies allegedly offering doctors expensive gifts, overseas trips, and other incentives to encourage the prescription of particular drugs.
The Union government had earlier said that the existing Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024, was functioning satisfactorily in addressing unethical marketing practices.
However, it acknowledged a regulatory gap when it came to bringing pharmaceutical companies within a statutory framework.
The committee will give its recommendations in terms of the court's previous directives and observations, and the matter will be placed before the court on January 29, 2027, to show compliance with the orders.
Justice Mehta said the court has directed the Union of India to constitute the committee and give its recommendations.
Key facts
- The Supreme Court directed the Union government to form a committee to regulate pharma marketing practices.
- The committee will examine whether pharmaceutical companies should be brought under a legally enforceable framework.
- The petition was filed by the Federation of Medical and Sales Representatives’ Associations of India (FMRAI).
- The matter will be placed before the court on January 29, 2027, to show compliance with the orders.
Three perspectives
Neutral
The Supreme Court's order aims to curb unethical marketing practices by pharmaceutical companies. The committee's recommendations will be crucial in regulating the industry. The court's decision is a significant step towards ensuring transparency in pharmaceutical marketing.
Positive
The formation of the committee is a positive step towards regulating the pharmaceutical industry and preventing unethical practices. The court's order will help to promote transparency and fairness in the industry.
Negative
The regulatory gap in the pharmaceutical industry has allowed companies to engage in unethical marketing practices, putting patients' lives at risk. The court's order is a belated attempt to address the issue, and its effectiveness remains to be seen.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.